» Articles » PMID: 35624206

NLRP3 Licenses NLRP11 for Inflammasome Activation in Human Macrophages

Overview
Journal Nat Immunol
Date 2022 May 27
PMID 35624206
Authors
Affiliations
Soon will be listed here.
Abstract

Intracellular sensing of stress and danger signals initiates inflammatory innate immune responses by triggering inflammasome assembly, caspase-1 activation and pyroptotic cell death as well as the release of interleukin 1β (IL-1β), IL-18 and danger signals. NLRP3 broadly senses infectious patterns and sterile danger signals, resulting in the tightly coordinated and regulated assembly of the NLRP3 inflammasome, but the precise mechanisms are incompletely understood. Here, we identified NLRP11 as an essential component of the NLRP3 inflammasome in human macrophages. NLRP11 interacted with NLRP3 and ASC, and deletion of NLRP11 specifically prevented NLRP3 inflammasome activation by preventing inflammasome assembly, NLRP3 and ASC polymerization, caspase-1 activation, pyroptosis and cytokine release but did not affect other inflammasomes. Restored expression of NLRP11, but not NLRP11 lacking the PYRIN domain (PYD), restored inflammasome activation. NLRP11 was also necessary for inflammasome responses driven by NLRP3 mutations that cause cryopyrin-associated periodic syndrome (CAPS). Because NLRP11 is not expressed in mice, our observations emphasize the specific complexity of inflammasome regulation in humans.

Citing Articles

Nature-derived microneedles with metal-polyphenolic networks encapsulation for chronic soft tissue defects repair: Responding and remodeling the regenerative microenvironment.

Zhu C, Fan Z, Cheng Z, Yin J, Qin L, Zhao X Mater Today Bio. 2025; 31:101539.

PMID: 40026624 PMC: 11869007. DOI: 10.1016/j.mtbio.2025.101539.


Molecular mechanisms of emerging inflammasome complexes and their activation and signaling in inflammation and pyroptosis.

Pandey A, Li Z, Gautam M, Ghosh A, Man S Immunol Rev. 2024; 329(1):e13406.

PMID: 39351983 PMC: 11742652. DOI: 10.1111/imr.13406.


Inflammasome activity regulation by PUFA metabolites.

Atalay Ekiner S, Gegotek A, Skrzydlewska E Front Immunol. 2024; 15:1452749.

PMID: 39290706 PMC: 11405227. DOI: 10.3389/fimmu.2024.1452749.


Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer.

Jin X, Jin W, Tong L, Zhao J, Zhang L, Lin N Acta Pharm Sin B. 2024; 14(7):2815-2853.

PMID: 39027232 PMC: 11252466. DOI: 10.1016/j.apsb.2024.04.020.


Spotlight on macrophage pyroptosis: A bibliometric and visual analysis from 2001 to 2023.

Peng Z, Xiao H, Tan Y, Zhang X Heliyon. 2024; 10(11):e31819.

PMID: 38845992 PMC: 11154638. DOI: 10.1016/j.heliyon.2024.e31819.


References
1.
Martinon F, Burns K, Tschopp J . The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002; 10(2):417-26. DOI: 10.1016/s1097-2765(02)00599-3. View

2.
Kesavardhana S, Malireddi R, Kanneganti T . Caspases in Cell Death, Inflammation, and Pyroptosis. Annu Rev Immunol. 2020; 38:567-595. PMC: 7190443. DOI: 10.1146/annurev-immunol-073119-095439. View

3.
Swanson K, Deng M, Ting J . The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019; 19(8):477-489. PMC: 7807242. DOI: 10.1038/s41577-019-0165-0. View

4.
Moretti J, Blander J . Increasing complexity of NLRP3 inflammasome regulation. J Leukoc Biol. 2020; 109(3):561-571. PMC: 8985609. DOI: 10.1002/JLB.3MR0520-104RR. View

5.
Booshehri L, Hoffman H . CAPS and NLRP3. J Clin Immunol. 2019; 39(3):277-286. PMC: 8575304. DOI: 10.1007/s10875-019-00638-z. View